Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy

PRIMARY OBJECTIVES:

I. Compare the genetic profile of the tumor after progression has occurred, to the tumor
prior to treatment.

SECONDARY OBJECTIVES:

I. Additional molecular patterns, beyond genetics, will be analyzed, including ribonucleic
acid (RNA) and protein expression.

OUTLINE:

Tissue and blood samples are collected for genetic analysis via sequencing from patients
receiving gemcitabine hydrochloride intravenously or gemcitabine hydrochloride and
paclitaxel albumin-stabilized nanoparticle formulation. Chemotherapy is not part of the
protocol. Per standard of care, patients receive gemcitabine hydrochloride (IV) the first 3
of 4 weeks (qw 3/4 wk) or gemcitabine hydrochloride and paclitaxel albumin-stabilized
nanoparticle formulation IV qw 3/4 wk in the absence of disease progression or recurrence.

Inclusion Criteria:

1. Suspected or confirmed pancreatic adenocarcinoma, any stage

2. >18 years of age

3. No prior systemic chemotherapy for pancreatic cancer, or currently undergoing
first-line treatment for pancreatic cancer, or completed only first-line treatment
for pancreatic cancer

4. A plan to undergo gemcitabine-based chemotherapy at Thomas Jefferson or a
collaborating institution

5. Abdominal/pelvic CT scan or MRI within 4 months of the study

6. Signed study-specific informed consent

Exclusion Criteria:

1. Pregnancy

2. Prior systemic chemotherapy for pancreatic cancer

3. Gender/Minority/Pediatric Inclusion for Research